DARE — Dare Bioscience Share News
0.000.00%
Last trade - 00:00- $12.70m
- $5.98m
- $1.03m
Brief: Daré Bioscience CEO Sabrina Martucci Johnson Named To Forbes 2026 “50 Over 50 Innovation” List
NASDAQ RESUMED AT 12:50 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:45 PM
Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Dare Bioscience Q2 net loss narrows as revenue rises, R&D expenses decline
Dare Bioscience Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Daré Bioscience Expands Access Options For Dare To Play™ And Specialized Menopause Care Through Strategic Collaboration With Mymenopauserx
Brief: Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv
Brief: Daré Bioscience Reports First Quarter 2026 Financial Results
Daré Bioscience Q1 net loss narrows as operating expenses fall
Brief: Positive Interim Phase 3 Results Highlight Potential Of Ovaprene®, Novel Hormone-Free Contraceptive
U.S. STOCKS ON THE MOVE-Walt Disney, BankUnited, copper miners
U.S. STOCKS ON THE MOVE-Ideaya Biosciences, Omnicom Group, Targa Resources
U.S. STOCKS ON THE MOVE-Barrick Mining, Tesla, Accenture
Daré Bioscience rises as Bayer exits Ovaprene partnership deal
Brief: Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data
U.S. STOCKS ON THE MOVE- Shoe Carnival, Leidos Holdings, copper miners
Maxim upgrades Daré Bioscience on extended cash runway, commercial launch
Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary